Laboratory testing plays an important role in diagnostics/staging, monitoring and prognosis of tumour diseases. In isolated cases, tumour markers can also be used for screening purposes. Different classes of analytes, such as carbohydrate antigens, organ-specific biomarker and nucleic acids, come into question as tumour markers. Most tests are carried out using serum and plasma samples, but in some cases whole blood, CSF, urine, faeces and tissue may be indicated. In particular, fine-tissue tests enable therapy stratification and thus patient-specific medication recommendations in many cases.
Pharmacogenetic testing helps predict the effectiveness of cytostatics or an increased risk for side effects.
Limbach Gruppe offers a full test portfolio covering the whole range of tumour markers available in laboratory medicine. Combined with our medical expertise, we help you ensure successful treatment outcomes.In addition, various methods of genetic diagnostics are available for classification and risk assessment of haemato-oncological diseases.
In addition, various methods of genetic diagnostics are available for classification and risk assessment of haemato-oncological diseases.
- Wide range of tumour markers for all solid tumour entities
- Detailed counselling on the choice of tumour markers suited for specific diagnostic consideration
- Therapeutic drug monitoring for cytostatics
- Pharmacogenetic testing for predictive therapy planning
- Innovative test methods (liquid biopsy)
- Phenotyping of haematological neoplasms
- Blood count differentiation, flow cytometry
- Molecular diagnostic characterisation of haematological neoplasms
- Molecular cytogenetic testing (fluorescence in situ hybridisation, FISH) in myeloid and lymphatic diseases (e.g. B-NHL, MDS, MPN, plasmacytoma, etc.)
- PCR-based techniques e.g. for detection of BCR/ABL1 rearrangement (M-bcr) and monitoring therapy progress, JAK2 V617F point mutation, mutations in calreticulin gene and MPL gene, TP53 gene mutation, etc.)
- Chromosome analysis for classification and risk stratification of haematopoietic neoplasms
- Molecular diagnostic characterisation of solid tumours
Tumour tissue tests enable therapy stratification and risk classification for a large variety of neoplasms. Relevant target genes include EGFR, KRAS, NRAS, HRAS and BRAF, PKI3, RET, TP53 and MSI status.
Laboratory testing for acquired genetic defects, e.g. leukaemia and solid tumours, is not subject to the German Genetic Diagnostics Act (Gendiagnostikgesetz, GenDG).
